In a groundbreaking move, President Trump has negotiated significant price reductions for popular weight loss medications, bringing costs down to as low as $50 per month for eligible patients. Find out how these changes will affect access to essential treatments!
In a groundbreaking move, President Trump announces deals with Eli Lilly and Novo Nordisk to reduce obesity drug prices, making treatments more accessible for millions of Americans. Medicare coverage for GLP-1 drugs starts in 2026, changing the landscape of obesity treatment.
In a bold move, Pfizer has filed a lawsuit against Novo Nordisk and Metsera, claiming their merger violates antitrust laws and threatens competition in the obesity drug market.
As demand for weight loss and diabetes drugs surges, Eli Lilly and Novo Nordisk dominate the market. Discover the challenges, competition, and future of this booming industry.
Eli Lilly's new obesity pill, orforglipron, faces tough competition but could disrupt the weight loss market. Despite underwhelming trial results, analysts see potential for success due to manufacturing advantages and pricing strategies.
Eli Lilly announces a dramatic price increase for its diabetes medication Mounjaro in the UK, raising the monthly cost from £122 to £330. This change affects private buyers but not NHS prescriptions. Learn more about the implications!
A new regulator confirmation links Ozempic to a rare eye condition, NAION, affecting diabetes patients. This revelation raises concerns about potential blindness risks associated with semaglutide. Discover the implications for users.
In a surprising move, Lars Fruergaard Jørgensen is stepping down as CEO of Novo Nordisk after years of leading the company through a successful phase in obesity and diabetes medications. As the search for his successor begins, what does this mean for the future of the pharmaceutical giant?
In a surprising move, Novo Nordisk CEO Lars Fruergaard Jorgensen steps down as the company faces significant market challenges and competition from Eli Lilly's Zepbound. With share prices plummeting, the board seeks new leadership to navigate the turbulent landscape.
European bourses opened mixed as the U.K. markets remained closed for a bank holiday. Investors are keenly awaiting economic data and earnings reports, including major companies like Novo Nordisk and BMW.
